+7 (495) 414-60-88
Moscow, 3rd Cherepkovskaya str. 15A
Antiretroviral therapy Phosphazid, lamivudine and EFV: portability and undesirable effects
Purpose: to evaluate the tolerability and adverse affects of antiretroviral therapy (APT) with the use of domestic product Phophazid.
Patients and methods: the study included 23 patients in the age of 19-39 years with HIV-infection under the supervision of the Centre for the prevention of AIDS city of Perm in 2008 - 2009. Many of them are women and 5 (22%) men C3 ('6%) and 4B (11 %j stages of HIV infection (V.V. Pokrovskiy, 2006) for 48 weeks patients take treatment according to national Protocol treatment of HIV-infection in adults FAZT-ZTS+EFV Фосфазид; (FAZT. никавир) (NRTI class) manufacture «LLC - AZT PHARMA TO B.» derivative fosfaurilirovannoe AZT, used per os in the form of tablets on 0 4 grams twice a day. Lamivudine (CCTV) and efavirenz <EFV) were used in standard doses Observation of the tolerability of drugs and undesirable effects was carried out in the dynamics of the infection process with research гемограммы and biochemical blood analysis performed after 4 weeks and then every 3 months with the help of гемоанализатора MEK-7222 and on automated analyzer Coneiab 20 with ионосепективным unit.
Results: the treatment of фосфазидом, lamivudine and EFV showed a high virological and immunological effectiveness, was divided all patients without any clinical and laboratory adverse events. Of the therapy has also contributed to the relief of anemia, already after 4 weeks in patients, there was an increased level of hemoglobin with 110.8 + 2,23 l to 123,8 + 2.59 (p < 0.05).
Conclusions: the use of APT with the inclusion of the domestic product фосфазид demonstrated good tolerance and no unwanted effects.
Ivanova E.S., Vorobyova H.H Khafizov K.M.
The regional center for prevention and control of AIDS and infectious diseases, Perm;
Perm state medical Wagner Academy.